Jim Werngren
About
Jim Werngren is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology.
According to data from OpenAlex, Jim Werngren has authored 62 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Infectious Diseases, 57 papers in Epidemiology and 16 papers in Molecular Biology. Recurrent topics in Jim Werngren's work include Tuberculosis Research and Epidemiology (59 papers), Mycobacterium research and diagnosis (51 papers) and Cancer therapeutics and mechanisms (10 papers). Jim Werngren is often cited by papers focused on Tuberculosis Research and Epidemiology (59 papers), Mycobacterium research and diagnosis (51 papers) and Cancer therapeutics and mechanisms (10 papers). Jim Werngren collaborates with scholars based in Sweden, United Kingdom and China. Jim Werngren's co-authors include Sven Hoffner, Sven Hoffner, Pontus Juréen, Mikael Mansjö, Thomas Schön, Kristian Ängeby, Erik Sturegård, Christian G. Giske, Gunnar Kahlmeter and Erja Chryssanthou and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Clinical Microbiology.
In The Last Decade
Jim Werngren
62 papers receiving 1.5k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jim Werngren Sweden | 21 | 1.2k | 1.1k | 389 | 342 | 234 | 62 | 1.5k | ||
| Frederick A. Sirgel South Africa | 18 | 1.2k 1.0× | 984 0.9× | 307 0.8× | 382 1.1× | 149 0.6× | 24 | 1.5k | ||
| Deepak V. Almeida United States | 27 | 1.7k 1.4× | 1.5k 1.4× | 591 1.5× | 445 1.3× | 252 1.1× | 51 | 2.1k | ||
| Vanessa Mathys Belgium | 21 | 900 0.7× | 742 0.7× | 466 1.2× | 236 0.7× | 146 0.6× | 52 | 1.3k | ||
| Khye Seng Goh Guadeloupe | 27 | 1.2k 0.9× | 1.3k 1.2× | 436 1.1× | 349 1.0× | 174 0.7× | 52 | 1.7k | ||
| Jurriaan E.M. de Steenwinkel Netherlands | 18 | 610 0.5× | 493 0.5× | 250 0.6× | 151 0.4× | 150 0.6× | 49 | 959 | ||
| Rosilene Fressatti Cardoso Brazil | 23 | 731 0.6× | 629 0.6× | 416 1.1× | 192 0.6× | 150 0.6× | 123 | 1.5k | ||
| Salman H. Siddiqi United States | 20 | 2.3k 1.9× | 2.4k 2.2× | 492 1.3× | 663 1.9× | 227 1.0× | 43 | 2.9k | ||
| T M Arain United States | 9 | 1.2k 1.0× | 947 0.9× | 723 1.9× | 219 0.6× | 215 0.9× | 9 | 1.6k | ||
| Devyani Deshpande United States | 26 | 1.3k 1.1× | 1.1k 1.0× | 248 0.6× | 174 0.5× | 276 1.2× | 58 | 1.7k | ||
| Asesh Banerjee United States | 9 | 924 0.8× | 776 0.7× | 571 1.5× | 213 0.6× | 238 1.0× | 11 | 1.4k |
Countries citing papers authored by Jim Werngren
Since
Specialization
Citations
This map shows the geographic impact of Jim Werngren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Werngren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Werngren more than expected).
Fields of papers citing papers by Jim Werngren
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jim Werngren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Werngren. The network helps show where Jim Werngren may publish in the future.
Co-authorship network of co-authors of Jim Werngren
This figure shows the co-authorship network connecting the top 25 collaborators of Jim Werngren. A scholar is included among the top collaborators of Jim Werngren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Werngren. Jim Werngren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mansjö, Mikael, et al.. (2024). Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the Mycobacterium tuberculosis complex based on the EUCAST reference protocol. Antimicrobial Agents and Chemotherapy. 69(2). e0094624–e0094624.
2.
Forsman, Lina Davies, Jerker Jonsson, Ramona Groenheit, et al.. (2024). Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis. International Journal of Antimicrobial Agents. 64(4). 107302–107302.
3.
Vilchèze, Catherine, Jim Werngren, Arnold Bainomugisa, et al.. (2023). Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 68(1). e0109623–e0109623.
4.
Anthony, Richard, Ramona Groenheit, Mikael Mansjö, Rina de Zwaan, & Jim Werngren. (2023). The Relative Positioning of Genotyping and Phenotyping for Tuberculosis Resistance Screening in Two EU National Reference Laboratories in 2023. Microorganisms. 11(7). 1809–1809.
5.
Wijkander, Maria, Ramona Groenheit, Mikael Mansjö, et al.. (2023). In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex. Microbiology Spectrum. 11(5). e0178123–e0178123.
6.
Mansjö, Mikael, et al.. (2022). Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study. Antimicrobial Agents and Chemotherapy. 66(6). e0207521–e0207521.
7.
Mansjö, Mikael, et al.. (2022). The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 66(12). e0102622–e0102622.
8.
Hu, Yi, Xubin Zheng, Lina Davies Forsman, et al.. (2021). Emergence of additional drug resistance during treatment of multidrug-resistant tuberculosis in China: a prospective cohort study. Clinical Microbiology and Infection. 27(12). 1805–1813.
9.
Enkirch, Theresa, et al.. (2020). Systematic Review of Whole-Genome Sequencing Data To Predict Phenotypic Drug Resistance and Susceptibility in Swedish Mycobacterium tuberculosis Isolates, 2016 to 2018. Antimicrobial Agents and Chemotherapy. 64(5).
10.
Schön, Thomas, Claudio U. Köser, Jim Werngren, et al.. (2020). What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. Clinical Microbiology and Infection. 26(11). 1453–1455.
11.
Kontsevaya, Irina, et al.. (2019). Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review. European Journal of Clinical Microbiology & Infectious Diseases. 39(3). 415–426.
12.
Zheng, Qi & Jim Werngren. (2018). An unbiased attitude is vital to exploring the Beijing genotype of Mycobacterium tuberculosis. Tuberculosis. 111. 193–197.
13.
Werngren, Jim, Erik Alm, & Mikael Mansjö. (2017). Non- pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?. Journal of Clinical Microbiology. 55(6). 1920–1927.
14.
Anthony, Richard, et al.. (2016). New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens. International Journal of Mycobacteriology. 5. S71–S72.
15.
Zheng, Xubin, Rongrong Zheng, Yi Hu, et al.. (2016). Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China. Antimicrobial Agents and Chemotherapy. 60(8). 4786–4792.
16.
Hu, Yi, Qi Zhao, Jim Werngren, et al.. (2015). Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment. BMC Infectious Diseases. 16(1). 4–4.
17.
Drobniewski, Francis, et al.. (2014). Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 69(11). 3001–3005.
18.
Kohan, Leila, et al.. (2011). Evaluation of loop mediated isothermal amplification for diagnosis of Mycobacterium tuberculosis complex in clinical samples. AFRICAN JOURNAL OF BIOTECHNOLOGY. 10(26). 5096–5101.
19.
Juréen, Pontus, Jim Werngren, & Sven Hoffner. (2004). Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis. 84(5). 311–316.
20.
Ängeby, Kristian, et al.. (2003). Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis. Clinical Microbiology and Infection. 9(11). 1148–1152.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Frederick A. Sirgel Breakdown of academic impact, for papers by Deepak V. Almeida Breakdown of academic impact, for papers by Vanessa Mathys Breakdown of academic impact, for papers by Khye Seng Goh Breakdown of academic impact, for papers by Jurriaan E.M. de Steenwinkel Breakdown of academic impact, for papers by Rosilene Fressatti Cardoso Breakdown of academic impact, for papers by Salman H. Siddiqi Breakdown of academic impact, for papers by T M Arain Breakdown of academic impact, for papers by Devyani Deshpande Breakdown of academic impact, for papers by Asesh Banerjee